Clinical trials: Patients With Cancer
Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis and Ureter Urothelial Carcinoma
Cisplatin and Gemcitabine Hydrochloride With or Without Berzosertib in Treating Patients With Metastatic Urothelial Cancer
This phase II trial studies how well cisplatin and gemcitabine hydrochloride with or without berzosertib works in treating patients with urothelial cancer that has spread to other places in the body (metastatic).
- Conditions
- Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis and Ureter Urothelial Carcinoma, Metastatic Ureter Urothelial Carcinoma, Stage IV Bladder Urothelial Carcinoma AJCC v7
- Trial name
- NCT02567409
- Testing
- Berzosertib, Cisplatin, Gemcitabine Hydrochloride
- Where
- 39 sites in United States
- Volunteers
- 87 people
- Sponsor
- National Cancer Institute (NCI)
Extensive-Stage Small Cell Lung Cancer
Sunitinib Maintenance Therapy After Induction Platinum-Based Chemotherapy in Patients With ES-SCLC
The goal of this study is to determine the progression-free survival rate in patients with extensive-stage small cell lung cancer who had achieved complete response, partial response, or stable disease with their previous…
- Trial name
- NCT00616109
- Testing
- sunitinib
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of Michigan Rogel Cancer Center
Neoplasms
An Extension Study to Provide Continued Bevacizumab Therapy to Participants With Solid Tumors Who Were Previously Enrolled in a Roche/Genentech Sponsored Study
This single-arm, open-label, multicenter extension study will provide continued bevacizumab therapy to participants with solid tumors who were previously enrolled in a Roche/Genentech sponsored study and who derived benefit from…
- Trial name
- NCT01588184
- Testing
- Bevacizumab
- Where
- 73 sites in Austria, Brazil and 19 more
- Volunteers
- 95 people
- Sponsor
- Hoffmann-La Roche
Advanced or Metastatic Non-small Cell Lung Cancer
A Randomized Phase 2 Trial of TAS-114 in Combination With S-1 Versus S-1
This is a randomized, open-label, Phase 2 study of TAS-114 administered in combination with S-1, to investigate the efficacy, safety and tolerability of the TAS-114/S-1 regimen in patients with advanced or metastatic NSCLC.
- Trial name
- NCT02855125
- Testing
- TAS-114, S-1
- Where
- 30 sites in United States, France and 4 more
- Volunteers
- 128 people
- Sponsor
- Taiho Oncology, Inc.
Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia
Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia
This randomized phase III trial is studying dexamethasone to see how well it works compared to prednisone during induction therapy.
- Conditions
- Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia, Childhood B Acute Lymphoblastic Leukemia
- Trial name
- NCT00075725
- Testing
- Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride
- Where
- 234 sites in United States, Australia and 3 more
- Volunteers
- 3,154 people
- Sponsor
- Children's Oncology Group
Head and Neck Cancer, Precancerous/Nonmalignant Condition
Photodynamic Therapy With Porfimer Sodium in Treating Patients With Precancerous Lesions, Cancer, or Other Disease of the Aerodigestive Tract
RATIONALE: Photodynamic therapy uses a drug that becomes active when it is exposed to a certain kind of light. When the drug is active, precancerous cells and cancer cells are killed.
- Trial name
- NCT00453336
- Testing
- Porfimer Sodium, Photodynamic Therapy
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- University of Miami
Choriocarcinoma
TRC105 Combined With Standard-dose Bevacizumab for Two Patients With Metastatic And Refractory Choriocarcinoma
The purpose of this study is to determine whether TRC105 in combination with Bevacizumab is effective in the treatment of two patients with metastatic and refractory choriocarcinoma.
- Trial name
- NCT02396511
- Testing
- TRC105, Bevacizumab
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Tracon Pharmaceuticals Inc.
Ovarian Cancer
NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer
This study was designed to evaluate the effect of two dose levels of NUC-1031 (500 mg/m2 and 750mg/m2) in patients with ovarian cancer.
- Trial name
- NCT03146663
- Testing
- NUC-1031 500 mg, NUC-1031 750mg
- Where
- 17 sites in United States, United Kingdom
- Volunteers
- 53 people
- Sponsor
- NuCana plc
Adenosquamous Lung Carcinoma, Bronchioloalveolar Carcinoma
MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy
This phase II trial studies the side effects and how well Akt inhibitor MK2206 (MK2206) and erlotinib hydrochloride works in treating patients with advanced non-small cell lung cancer who have progressed after previous response…
- Conditions
- Adenosquamous Lung Carcinoma, Bronchioloalveolar Carcinoma, Large Cell Lung Carcinoma, Lung Adenocarcinoma
- Trial name
- NCT01294306
- Testing
- Akt Inhibitor MK2206, Erlotinib Hydrochloride, Laboratory Biomarker Analysis
- Where
- 7 sites in United States
- Volunteers
- 80 people
- Sponsor
- National Cancer Institute (NCI)
Skin Cancer
Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol
Transplant recipients have a high risk to develop skin malignancies. This effect depends on the one hand on the immunosuppressive drugs themselves (i.e., azathioprine) and relates on the other hand on the dosage (i.e.…
- Trial name
- PROSKIN (NCT00866684)
- Testing
- Sirolimus, Azathioprine, Mycophenolate
- Where
- 15 sites in Germany
- Volunteers
- 44 people
- Sponsor
- Charite University, Berlin, Germany
Hepatocellular Carcinoma
A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib
This is a Phase 3 multicenter, randomized study evaluating the safety and efficacy of ramucirumab DP plus BSC as a double-blind, placebo-controlled (placebo plus BSC) comparison.
- Trial name
- REACH (NCT01140347)
- Testing
- Ramucirumab DP (IMC-1121B), BSC
- Where
- 146 sites in United States, Australia and 25 more
- Volunteers
- 565 people
- Sponsor
- Eli Lilly and Company
Lung Cancer
Neoadjuvant Platinum-based Chemotherapy for Patients With Resectable , Non-small Cell Lung Cancer With Switch to Chemotherapy Alternative in Nonresponders (NEOSCAN)
The purpose of this study is to test a new approach to the use of standard drugs before surgery in patients with lung cancer. This study will find out what effects, good and/or bad, that this approach has on the cancer.
- Trial name
- NCT01443078
- Testing
- pemetrexed, cisplatin, Carboplatin
- Where
- 5 sites in United States
- Volunteers
- 42 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Triple-negative Breast Cancer
A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer
This is a global Phase III, double-blind, randomized, placebo-controlled study designed to evaluate the efficacy and safety of neoadjuvant treatment with atezolizumab (anti-programmed death-ligand 1 [anti-PD-L1] antibody) and…
- Trial name
- IMpassion031 (NCT03197935)
- Testing
- Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody, Nab-paclitaxel, Doxorubicin
- Where
- 68 sites in United States, Australia and 11 more
- Volunteers
- 333 people
- Sponsor
- Hoffmann-La Roche
Cancer of Head and Neck
Single-arm Phase II Study of NDURE for Patients With HNC
This study will evaluate whether a new patient navigation intervention can decrease delays starting post-operative radiation therapy after surgery for white and African-American head and neck cancer patients.
- Trial name
- NDURE (NCT03821064)
- Testing
- Patient Navigation
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Medical University of South Carolina
Adenosquamous Lung Carcinoma, Bronchioloalveolar Carcinoma
Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung Cancer
This randomized phase II trial studies how well chemotherapy and radiation therapy given with or without metformin hydrochloride works in treating patients with stage III non-small cell lung cancer.
- Conditions
- Adenosquamous Lung Carcinoma, Bronchioloalveolar Carcinoma, Large Cell Lung Carcinoma, Lung Adenocarcinoma
- Trial name
- NCT02186847
- Testing
- Radiation Therapy, Carboplatin, Metformin
- Where
- 223 sites in United States, Canada and 1 more
- Volunteers
- 170 people
- Sponsor
- NRG Oncology
Leukemia, Myelodysplastic Syndromes
Azacitidine, Darbepoetin Alfa, and Erythropoietin and Filgastrim (G-CSF) in Treating Patients With Myelodysplastic Syndromes
RATIONALE: Drugs used in chemotherapy, such as azacitidine, work in different ways to stop the growth of abnormal cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00398047
- Testing
- Azacitadine and Hematopoietic Growth Factors
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Wake Forest University Health Sciences
Acute Myeloid Leukemia
Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of ASP2215 in Patients With Relapsed or Refractory Acute Myeloid Leukemia
The objective of this study was to assess the safety and tolerability, including the maximum tolerated dose, of gilteritinib in participants with relapsed or treatment-refractory acute myeloid leukemia (AML).
- Trial name
- NCT02014558
- Testing
- Gilteritinib, Voriconazole, Midazolam
- Where
- 26 sites in United States, Germany and 1 more
- Volunteers
- 265 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Metastatic Pancreatic Ductal Adenocarcinoma
A Phase 1B Study of Canakinumab, Spartalizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer (PC) Patients
This study combines canakinumab (ACZ885), a high-affinity human anti-interleukin-1β (IL-1β) monoclonal antibody (mAb), and spartalizumab (PDR001), a mAb directed against human Programmed Death-1 (PD-1), with the chemotherapy…
- Trial name
- PanCAN-SR1 (NCT04581343)
- Testing
- Canakinumab injection; spartalizumab, nab-paclitaxel, gemcitabine
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Pancreatic Cancer Action Network
Melanoma
Phase II Biomarker Study Comparing the Combination of BRAF Inhibitor Dabrafenib With MEK Inhibitor Trametinib Versus the Combination After Monotherapy With Dabrafenib or Trametinib
This is a three-arm, open-label, randomised Phase II study to evaluate whether the different sequencing of dabrafenib and trametinib monotherapies and the upfront combination has an impact on translational or clinical activity in…
- Trial name
- NCT02314143
- Testing
- Dabrafenib, Trametinib
- Where
- 7 sites in France, Spain
- Volunteers
- 48 people
- Sponsor
- GlaxoSmithKline
Glioma, Glioblastoma
Solriamfetol in Improving Sleep in Patients With Grade II-IV Glioma
This phase II trial studies the side effects of solriamfetol in improving sleep in patients with grade II-IV glioma. Solriamfetol is a wakefulness-promoting drug.
- Trial name
- JAZZ (NCT03868943)
- Testing
- Soliramfetol
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Wake Forest University Health Sciences
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.